Showing results (381-390 of 528) with videos related to
Sort By:
Pageof 53
Breast Cancer Research and Treatment|October 20, 2024
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical recordsPaul Cottu, Sue Cheeseman, Peter Hall, et al.Genes|June 26, 2026
LANTERN 2: Association Between Gene Molecular Profile and STAS in Lung Adenocarcinoma: A Comparative Analysis in a Prospective Real-World PopulationCarolina Sassorossi, Davide Dalfovo, Elisa De Paolis, et al.Clinical Lung Cancer|August 5, 2019
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural MesotheliomaClaudia Proto, Diego Signorelli, Sandra Mallone, et al.Molecular Cancer|May 11, 2017
Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulationTeresa Bellissimo, Federica Ganci, Enzo Gallo, et al.Journal of Surgical Oncology|February 22, 2023
A prognostic score from a multicentric retrospective analysis of patients affected by sarcoma with metachronous lung metastases undergoing metastasectomyFilippo Tommaso Gallina, Enrico Melis, Luca Bertolaccini, et al.International Journal of Molecular Sciences|April 14, 2026
LANTERN-XGB: An Interpretable Multi-Modal Machine Learning for Improving Clinical Decision-Making in Lung CancerDavide Dalfovo, Carolina Sassorossi, Elisa De Paolis, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapyMichele Milella, Carmen Nuzzo, Emilio Bria, et al.European Journal of Cancer (Oxford, England : 1990)|December 23, 2025
PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world studyMaria Vittoria Dieci, Grazia Vernaci, Chiara Colangelo, et al.Clinical Lung Cancer|February 9, 2021
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase InhibitorsMiriam Grazia Ferrara, Maurizio Martini, Ettore D'Argento, et al.Anticancer Research|September 12, 2013
HER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapyMatteo Brunelli, Erminia Manfrin, Emilio Bria, et al.Pageof 53